RU2003105882A - Упорядоченный железосодержащий белок-2 в качестве диагностического средства при нейродегенеративных заболеваниях - Google Patents
Упорядоченный железосодержащий белок-2 в качестве диагностического средства при нейродегенеративных заболеваниях Download PDFInfo
- Publication number
- RU2003105882A RU2003105882A RU2003105882/13A RU2003105882A RU2003105882A RU 2003105882 A RU2003105882 A RU 2003105882A RU 2003105882/13 A RU2003105882/13 A RU 2003105882/13A RU 2003105882 A RU2003105882 A RU 2003105882A RU 2003105882 A RU2003105882 A RU 2003105882A
- Authority
- RU
- Russia
- Prior art keywords
- protein
- probe
- antibody
- mutant
- purified
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 235000018102 proteins Nutrition 0.000 claims 16
- 102000004169 proteins and genes Human genes 0.000 claims 16
- 108090000623 proteins and genes Proteins 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 239000000523 sample Substances 0.000 claims 13
- 238000000034 method Methods 0.000 claims 9
- 239000012472 biological sample Substances 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 230000035772 mutation Effects 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 230000004770 neurodegeneration Effects 0.000 claims 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 230000009870 specific binding Effects 0.000 claims 3
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 102000008300 Mutant Proteins Human genes 0.000 claims 1
- 108010021466 Mutant Proteins Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108091005461 Nucleic proteins Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000005284 excitation Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 238000003317 immunochromatography Methods 0.000 claims 1
- 238000001114 immunoprecipitation Methods 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22286300P | 2000-08-04 | 2000-08-04 | |
| US60/222,863 | 2000-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2003105882A true RU2003105882A (ru) | 2005-01-20 |
Family
ID=22834032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003105882/13A RU2003105882A (ru) | 2000-08-04 | 2001-08-06 | Упорядоченный железосодержащий белок-2 в качестве диагностического средства при нейродегенеративных заболеваниях |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20020165349A1 (enExample) |
| EP (1) | EP1355933A2 (enExample) |
| JP (1) | JP2004506420A (enExample) |
| CN (1) | CN100535004C (enExample) |
| AU (1) | AU2001284742A1 (enExample) |
| CA (1) | CA2417310A1 (enExample) |
| MX (1) | MXPA03000937A (enExample) |
| RU (1) | RU2003105882A (enExample) |
| WO (1) | WO2002012284A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| MXPA04007832A (es) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| ATE404877T1 (de) * | 2002-08-27 | 2008-08-15 | Kennedy Krieger Inst | Magnetische rezonanzbildgebung des mikrovaskulären blutvolumens |
| UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| HRP20060073B1 (hr) | 2003-07-23 | 2014-03-14 | Bayer Healthcare Llc | Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja |
| CN101010315A (zh) * | 2004-04-30 | 2007-08-01 | 拜耳制药公司 | 用于治疗癌症的取代的吡唑基脲衍生物 |
| JP4653542B2 (ja) * | 2005-04-06 | 2011-03-16 | 株式会社東芝 | 画像処理装置 |
| CN100448481C (zh) * | 2006-06-22 | 2009-01-07 | 中国科学院遗传与发育生物学研究所 | xCT蛋白及其编码基因的新用途 |
| WO2010068742A1 (en) * | 2008-12-12 | 2010-06-17 | Beckman Coulter, Inc. | Multicolor flow cytometry compositions containing unconjugated phycobiliproteins |
| US8580230B2 (en) * | 2009-02-23 | 2013-11-12 | Kent State University | Materials and methods for MRI contrast agents and drug delivery |
| EP2253716A1 (en) * | 2009-05-15 | 2010-11-24 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Diagnostic methods for the prognosis of a brain tumor |
| EP2642289A1 (en) | 2012-03-20 | 2013-09-25 | Sensirion AG | Portable electronic device |
| US9259357B2 (en) | 2014-04-16 | 2016-02-16 | Loma Linda University | Composition, preparation, and use of chitosan shards for biomedical applications |
| CN107636468A (zh) * | 2015-04-02 | 2018-01-26 | Crc心理健康有限公司 | 用于预测认知退化的风险的方法 |
| WO2018148788A1 (en) * | 2017-02-17 | 2018-08-23 | Crc For Mental Health Ltd | Method for predicting risk and rate of amyloid deposition and plaque formation |
| IT201700105483A1 (it) * | 2017-09-21 | 2019-03-21 | Braindtech S R L | Metodo per la diagnosi e la prognosi di patologie neurodegenerative e neuroinfiammatorie |
| JP6737995B2 (ja) * | 2018-11-29 | 2020-08-12 | 株式会社Ｒｅｓｖｏ | 精神疾患発症危険状態の診断用バイオマーカー |
| CN114446392B (zh) * | 2022-01-21 | 2024-01-30 | 华东理工大学 | 确认蛋白质与核酸适配体结合时的关键精氨基酸残基位点的方法 |
| CN114457067B (zh) * | 2022-02-10 | 2024-10-25 | 中国科学院天津工业生物技术研究所 | 一种低成本快速去除dna合成中错误的方法 |
| CN117417999B (zh) * | 2023-11-27 | 2025-07-25 | 河南省人民医院 | 一种与ireb2基因相关的snp分子标记及其应用 |
-
2001
- 2001-08-06 WO PCT/US2001/024747 patent/WO2002012284A2/en not_active Ceased
- 2001-08-06 RU RU2003105882/13A patent/RU2003105882A/ru unknown
- 2001-08-06 CN CNB018148549A patent/CN100535004C/zh not_active Expired - Fee Related
- 2001-08-06 EP EP01963822A patent/EP1355933A2/en not_active Withdrawn
- 2001-08-06 CA CA002417310A patent/CA2417310A1/en not_active Abandoned
- 2001-08-06 US US09/924,396 patent/US20020165349A1/en not_active Abandoned
- 2001-08-06 JP JP2002518256A patent/JP2004506420A/ja active Pending
- 2001-08-06 MX MXPA03000937A patent/MXPA03000937A/es unknown
- 2001-08-06 AU AU2001284742A patent/AU2001284742A1/en not_active Abandoned
-
2005
- 2005-07-01 US US11/174,166 patent/US20050260669A1/en not_active Abandoned
-
2007
- 2007-06-27 US US11/769,503 patent/US20080020393A1/en not_active Abandoned
-
2009
- 2009-10-21 US US12/603,411 patent/US20100041060A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2417310A1 (en) | 2002-02-14 |
| WO2002012284A3 (en) | 2003-08-21 |
| WO2002012284A2 (en) | 2002-02-14 |
| MXPA03000937A (es) | 2004-08-02 |
| JP2004506420A (ja) | 2004-03-04 |
| AU2001284742A1 (en) | 2002-02-18 |
| EP1355933A2 (en) | 2003-10-29 |
| US20050260669A1 (en) | 2005-11-24 |
| CN100535004C (zh) | 2009-09-02 |
| US20080020393A1 (en) | 2008-01-24 |
| US20020165349A1 (en) | 2002-11-07 |
| US20100041060A1 (en) | 2010-02-18 |
| CN1556815A (zh) | 2004-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003105882A (ru) | Упорядоченный железосодержащий белок-2 в качестве диагностического средства при нейродегенеративных заболеваниях | |
| JP2004506420A5 (enExample) | ||
| JP4885122B2 (ja) | 癌、器官傷害、および筋肉リハビリテーション／運動過剰訓練についての診断の生物マーカーとしてのタンパク質分解マーカー | |
| AU633312B2 (en) | Diagnostic method for alzheimer's disease: examination of non-neural tissue | |
| US5434050A (en) | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease | |
| EP1325338A2 (en) | Diagnosis and treatment of alzheimer's disease | |
| JPWO2010052939A1 (ja) | アレルゲンのエピトープ又はその候補の検出方法及びその利用 | |
| EP1690870B1 (en) | Marker peptide for alzheimer's disease | |
| US6387639B1 (en) | Ma family polypeptides and anti-Ma antibodies | |
| EP1408333A2 (en) | Diagnosis and treatment of Alzheimer's disease | |
| WO2002088750A2 (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
| TWI541354B (zh) | 牙周病原菌血漿或血清抗體價檢查套組 | |
| CA2501464A1 (en) | Lmna gene and its involvement in hutchinson-gilford progeria syndrome (hgps) and arteriosclerosis | |
| US12000844B2 (en) | Diagnostic drug and diagnostic method for Alzheimer's disease | |
| EP1208381A2 (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
| JP7718270B2 (ja) | 血液試料を検体とするタウタンパク質検出方法 | |
| US20030092614A1 (en) | ADPI-41, a novel protein isolated from brain tissue homogenate and uses therefor | |
| RU2340900C2 (ru) | Диагностика аутизма | |
| WO2000055628A1 (en) | Proteins for diagnosis and treatment of breast cancer | |
| WO1999060122A1 (en) | Method for examining central nervous system diseases and method for screening remedies | |
| EP3654038A1 (en) | Biomarker for cognitive impairment disorders and detection method for cognitive impairment disorders using said biomarker | |
| CA2461199A1 (en) | Atlastin | |
| CN113846155A (zh) | 一种cdh23基因突变体及其检测的试剂盒与应用 | |
| JP2005124565A (ja) | 新規神経ペプチド及びその利用 | |
| JP2024158581A (ja) | 神経核内封入体病の検出抗体及びそれを用いた検出方法 |